Tie‑1 was detected in immersion fixed paraffin-embedded sections of human placenta using 8 µg/mL Goat Anti-Human Tie‑1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF619) overnight at 4 °C. Tissue was ...read more
HUVEC human umbilical vein endothelial cells were stained with Goat Anti-Human Tie‑1 Antigen Affinity‑purified Polyclonal Antibody (Catalog # AF619, filled histogram) or control antibody (Catalog # AB-108-C, open ...read more
Mouse myeloma cell line NS0-derived recombinant human Tie-1 Ala22-Gln760 Accession # P35590
Detects human Tie-1 in direct ELISAs and Western blots. In direct ELISAs, approximately 50% cross-reactivity with recombinant mouse Tie-1 is observed and less than 1% cross-reactivity with recombinant human Tie‑2 is observed.
Test in a species/application not listed above to receive a full credit towards a future purchase.
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
Reconstitute at 0.2 mg/mL in sterile PBS.
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for Tie-1 Antibody [Unconjugated]
JTK14soluble TIE1 variant 3
receptor tyrosine kinase
soluble TIE1 variant 1
soluble TIE1 variant 2
soluble TIE1 variant 5
TIEsoluble TIE1 variant 4
tyrosine kinase with immunoglobulin and epidermal growth factor homologydomains 1
tyrosine kinase with immunoglobulin-like and EGF-like domains 1
tyrosine-protein kinase receptor Tie-1
Tie-1/Tie (tyrosine kinase with Ig and EGF homology domains 1) and Tie-2/Tek comprise a receptor tyrosine kinase (RTK) subfamily with unique structural characteristics: two immunoglobulin-like domains flanking three epidermal growth factor (EGF)-like domains and followed by three fibronectin type III-like repeats in the extracellular region and a split tyrosine kinase domain in the cytoplasmic region. These receptors are expressed primarily on endothelial and hematopoietic progenitor cells and play critical roles in angiogenesis, vasculogenesis and hematopoiesis.
Human Tie-1 cDNA encodes a 1138 amino acid (aa) residue precursor protein with a 24 residue putative signal peptide, a 735 residue extracellular domain and a 354 residue cytoplasmic domain. Ligands which bind and activate Tie-1 have not been identified. Based on gene-targeting studies, the in vivo functions of Tie-1 have been shown to be related to endothelial cell differentiation and the maintenance of integrity of the endothelium.
Partanen, J. and D.J. Dumont (1999) Curr. Top. Microbiol. Immunol. 237:159
Sato, T.N. et al. (1995) Nature 376:70
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our Tie-1 Antibody [Unconjugated] and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.